Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC).

Trial Profile

Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Carboplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Apr 2016 Results (pooled analysis of NVALT-7 and GOIRC02-2006 studies, n = 390) published in the Annals of Oncology.
    • 07 Jul 2011 Pooled analysis results assessing overall survival outcomes presented at the 14th World Conference on Lung Cancer.
    • 07 Jun 2011 Pooled analysis results assessing overall survival presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top